This is the third HBV core inhibitor that ASMB has discontinued, but it’s hardly a surprising development. ASMB has yet to get anything right in HBV—please see #msg-167605073, #msg-168960516, and #msg-169454462 for details.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”